article thumbnail

Gluten in Medications: Why Labeling Matters for Patients With Celiac Disease

Drug Topics

Despite pleas from celiac disease advocates, the FDA still does not require drug manufacturers to note on the label whether a medication contains gluten.

Labelling 201
article thumbnail

Can Patient-Centered Prescription Labels Increase Medication Adherence?

Drug Topics

Researchers evaluated how changes in USP labeling standards have affected adherence across multiple classes of drugs.

Labelling 186
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure

STAT

Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a common form of heart failure, according to a new analysis that could boost the company’s efforts to expand the label for the blockbuster treatment. of those who received placebo.

Labelling 124
article thumbnail

Sarepta scores 'transformational' FDA label expansion for Duchenne gene therapy Elevidys

Fierce Pharma

The FDA has expanded the label for Sarepta's Elevidys to all Duchenne muscular dystrophy patients ages 4 and older. There’s no slowing the momentum of Sarepta’s groundbreaking Duchenne muscular dystrophy (DMD) gene therapy Elevidys—not even the failure of a confirmatory trial. |

Labelling 126
article thumbnail

Incyte looks to widen Monjuvi's net with label expansion bid after phase 3 lymphoma win

Fierce Pharma

Months after securing the full rights to anti-CD19 antibody Monjuvi (tafasitamab) from partner MorphoSys, Incyte has the data to potentially back a label expansion into lymphoma. | The company looks to file its drug for a follicular lymphoma indication as part of a later-line triple combo therapy by the end of the year.

Labelling 102
article thumbnail

STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label

STAT

regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its benefits for the heart, a move that could boost demand and insurance coverage for the already highly popular treatment. Novo said it has also filed for a label expansion in Europe and a decision is expected this year.

Labelling 141
article thumbnail

Sarepta bags key expansion to DMD gene therapy label in US

pharmaphorum

Sarepta gets best-case approval from the FDA for an expansion to the label for its Duchenne muscular dystrophy gene therapy Elevidys.

Labelling 111